Hemorrhoids Treatment Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), World Health Organization (WHO) Global Health Observatory, European Centre for Disease Prevention and Control (ECDC), Pan American Health Organization (PAHO), United Nations Population Fund (UNFPA), American Society of Colon and Rectal Surgeons (ASCRS), American Gastroenterological Association (AGA), Society for Surgery of the Alimentary Tract (SSAT), European Society of Coloproctology (ESCP), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Agency for Healthcare Research and Quality (AHRQ), EU Eurostat Health Database, OECD Health Statistics, and national health ministry reports from key markets (U.S. Department of Health & Human Services, NHS England, German Federal Ministry of Health, Japan Ministry of Health, Labour and Welfare). These sources were used to collect disease prevalence statistics, regulatory approval data, clinical safety studies, demographic trends, procedure volume analysis, and market landscape analysis for topical treatments, oral medications, minimally invasive procedures (rubber band ligation, sclerotherapy, infrared coagulation), and surgical interventions (hemorrhoidectomy, stapled hemorrhoidopexy).

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Product Development, regulatory affairs chiefs, and commercial directors from hemorrhoid treatment device manufacturers, pharmaceutical companies, and medical device OEMs. Demand-side sources consist of procurement leads from hospitals, specialty clinics, and retail pharmacy chains, as well as board-certified colorectal surgeons, gastroenterologists, general surgeons, and medical directors of ambulatory surgical centers. Market segmentation was validated, product pipeline timelines were confirmed, and insights regarding clinical adoption patterns, pricing strategies, reimbursement dynamics, and patient preference shifts toward minimally invasive treatments were gathered through primary research.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (38%), Europe (29%), Asia-Pacific (25%), Rest of World (8%)

Global market valuation was derived through revenue mapping, procedure volume analysis, and pharmaceutical sales data. The methodology included:

Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across topical treatments (creams, ointments, suppositories), oral medications (venoactive drugs, analgesics), minimally invasive procedures (band ligators, sclerotherapy injectors, infrared coagulators), and surgical procedures (excisional hemorrhoidectomy, stapled hemorrhoidopexy)

Analysis of reported and modeled annual revenues specific to hemorrhoids treatment portfolios

Coverage of manufacturers representing 72-78% of global market share in 2024

Extrapolation using bottom-up (procedure volume × ASP by country, prescription volume × drug pricing by region) and top-down (manufacturer revenue validation, pharmaceutical sales data triangulation) approaches to derive segment-specific valuations for treatment types, severity levels, patient demographics, and distribution channels